Immunocore Holdings plc (IMCR)
| Previous close | 59.85 |
| Open | 59.86 |
| Bid | 59.28 x 200 |
| Ask | 60.52 x 200 |
| Day's range | 59.86 - 60.25 |
| 52-week range | 42.21 - 76.98 |
| Volume | |
| Avg. volume | 416,701 |
| Market cap | 2.939B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 85.81 |
GuruFocus.comImmunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts
Comprehensive Analysis of Immunocore's Financial Performance and Strategic Updates
GlobeNewswireImmunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMC
- GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to ra
